GO:0043123 positive regulation of canonical NF-kappaB signal transduction: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043123 describes any process that activates or increases the frequency, rate or extent of the canonical NF-kappaB signaling cascade [1, 3].
• Canonical NF-kappaB activation is driven by IKK complex-mediated phosphorylation and degradation of IkappaB inhibitors, releasing RelA/p50 dimers to the nucleus [3, 8].
• Deregulated positive regulation of canonical NF-kappaB signaling is a hallmark of lymphoid malignancies, including Hodgkin lymphoma, and contributes to inflammatory and ischemic diseases [2, 3, 8].
• Key positive regulators include TNF, IL-1, TLR ligands, and downstream kinases such as IKKbeta and NEMO, which integrate diverse immune and stress signals [3, 8].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of positive regulators in disease contexts [5, 6].
• The term is distinct from non-canonical NF-kappaB signaling, which relies on NIK and p100 processing rather than IKKbeta-mediated IkappaB degradation.
Description
GO:0043123, positive regulation of canonical NF-kappaB signal transduction, is a Gene Ontology biological process term that captures any event that activates or increases the canonical NF-kappaB signaling cascade [1, 3]. The canonical pathway is a central mediator of inflammation, immune responses, cell survival, and proliferation, and its positive regulation is essential for mounting effective host defense [3, 8]. Because excessive or constitutive activation drives cancer, autoimmunity, and tissue injury, understanding the mechanisms that positively regulate this cascade is a major research focus [2, 3, 8]. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of the term, its molecular players, disease relevance, and experimental strategies for studying it [1, 3, 5, 6].
positive regulation of canonical NF-kappaB signal transduction At A Glance
| GO ID | GO:0043123 |
|---|---|
| GO term | positive regulation of canonical NF-kappaB signal transduction |
| Ontology | biological_process |
| Synonym | activation of I-kappaB kinase/NF-kappaB cascade; positive regulation of I-kappaB kinase/NF-kappaB cascade; upregulation of I-kappaB kinase/NF-kappaB cascade |
| Major function | Activation or enhancement of the canonical NF-kappaB signaling cascade, leading to nuclear translocation of RelA/p50 and target gene expression [3, 8] |
| Key upstream inducers | TNF, IL-1, TLR ligands, antigen receptor signals [3, 8] |
| Core kinases | IKKalpha, IKKbeta, NEMO (IKKgamma) [3, 8] |
| Inhibitory proteins | IkappaBalpha, IkappaBbeta, IkappaBepsilon [3, 8] |
| Disease relevance | Lymphoid malignancies, breast cancer, myocardial ischemia/reperfusion injury, multiple sclerosis [2, 3, 5, 6, 8] |
What Is GO:0043123?
According to QuickGO, GO:0043123 encompasses any process that activates or increases the frequency, rate or extent of a canonical NF-kappaB signaling cascade. In practice, this includes ligand binding to receptors such as TNF receptor or IL-1 receptor, recruitment of adaptor proteins, activation of the IKK complex, phosphorylation and degradation of IkappaB inhibitors, and nuclear translocation of NF-kappaB dimers that drive target gene transcription [3, 8]. The term is specific to the canonical (classical) pathway and excludes non-canonical NF-kappaB signaling, which depends on NIK-mediated p100 processing.
Why Is positive regulation of canonical NF-kappaB signal transduction Important in Cell Biology?
Positive regulation of canonical NF-kappaB signaling is critical because it governs the intensity and duration of inflammatory and immune responses, and its dysregulation is causally linked to cancer, autoimmune disease, and tissue damage [2, 3, 5, 8]. Understanding how this process is positively regulated provides mechanistic insight into disease pathogenesis and identifies targets for therapeutic intervention [3, 6, 8].
• Drives expression of pro-inflammatory cytokines and chemokines, amplifying immune responses [3, 8].
• Promotes cell survival and proliferation, contributing to tumorigenesis in lymphoid malignancies [3, 8].
• Mediates myocardial ischemic/reperfusion injury through IL-34-NF-kappaB signaling and macrophage recruitment.
• Controls CD4+ T cell function in multiple sclerosis and cancer, with RelA and c-Rel subunits playing selective roles.
• Is constitutively activated in breast cancer subtypes, supporting subtype-independent therapeutic targeting.
• Regulates chemokine production such as CXCL10 in breast cancer cells, influencing tumor microenvironment.
• Serves as a key node for host-pathogen interactions and inflammatory signaling [3, 8].
• Provides a mechanistic basis for CRISPR-based functional genomics in immune and cancer research [5, 6].
• Distinguishes canonical from non-canonical NF-kappaB signaling for precise experimental design.
• Offers biomarkers and targets for immunotherapy response prediction in immune-hot versus immune-cold tumors.
What Happens During positive regulation of canonical NF-kappaB signal transduction?
Receptor Engagement and Adaptor Recruitment
In simple terms: A signal molecule binds to a receptor on the cell surface, triggering a chain of protein interactions inside the cell.
Positive regulation begins when ligands such as TNF or IL-1 bind to their receptors, leading to recruitment of adaptor proteins like TRADD, TRAF2, and RIP1 [3, 8]. These events nucleate a signaling platform that activates downstream kinases, initiating the canonical cascade [3, 8].
IKK Complex Activation
In simple terms: A kinase complex called IKK gets switched on, which is the central step in turning on NF-kappaB.
The IKK complex, composed of IKKalpha, IKKbeta, and NEMO, is activated through phosphorylation of IKKbeta and NEMO [3, 8]. This activation is a hallmark of positive regulation and is required for subsequent phosphorylation of IkappaB proteins [3, 8].
IkappaB Phosphorylation and Degradation
In simple terms: The inhibitor that holds NF-kappaB in the cytoplasm gets tagged for destruction, freeing NF-kappaB to move.
Activated IKKbeta phosphorylates IkappaBalpha at serines 32 and 36, leading to its ubiquitination and proteasomal degradation [3, 8]. This step is essential for releasing NF-kappaB dimers, primarily RelA/p50, from cytoplasmic retention [3, 8].
Nuclear Translocation and Target Gene Activation
In simple terms: NF-kappaB moves into the nucleus and turns on genes that control inflammation and survival.
Free RelA/p50 dimers translocate to the nucleus and bind kappaB sites in DNA, activating transcription of target genes including cytokines, chemokines, and anti-apoptotic factors [3, 8]. This transcriptional output defines the functional consequence of positive regulation [3, 8].
Feedback and Fine-Tuning
In simple terms: The cell has built-in brakes to prevent the response from going out of control.
Positive regulation is balanced by negative feedback loops, including resynthesis of IkappaBalpha and deubiquitination of signaling intermediates [3, 8]. Dysregulation of these brakes can lead to constitutive NF-kappaB activity in disease [3, 8].
Key Genes Involved in GO:0043123 positive regulation of canonical NF-kappaB signal transduction
The following genes and proteins are central to positive regulation of canonical NF-kappaB signal transduction, based on verified literature [2, 3, 5, 6, 7, 8].
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNF | Ligand that triggers canonical NF-kappaB activation | Inflammatory disease models, cytokine signaling studies [3, 8] |
| IL1B | Ligand that activates IL-1 receptor and NF-kappaB | Inflammation and tissue injury research [3, 8] |
| TRAF2 | Adaptor protein recruiting IKK complex | Signal transduction and cancer studies [3, 8] |
| TRAF6 | Adaptor for TLR/IL-1R signaling | Innate immunity and inflammation [3, 8] |
| RIPK1 | Kinase scaffolding IKK activation | Cell death and inflammation crosstalk [3, 8] |
| IKBKB | IKKbeta kinase phosphorylating IkappaB | Core positive regulator, drug target [3, 8] |
| IKBKA | IKKalpha kinase with roles in canonical pathway | Immune regulation and cancer [3, 8] |
| IKBKG | NEMO regulatory subunit of IKK | Essential for IKK activation, disease mutations [3, 8] |
| NFKB1 | p50 subunit of NF-kappaB dimer | Transcription factor studies [3, 8] |
| RELA | p65 subunit of NF-kappaB dimer | T cell function and cancer |
| RELB | Non-canonical NF-kappaB subunit | Distinguishing pathways |
| NFKBIA | IkappaBalpha inhibitor | Feedback regulation and degradation studies [3, 8] |
| NFKBIB | IkappaBbeta inhibitor | Signal duration control [3, 8] |
| IL34 | Cytokine activating NF-kappaB in macrophages | Myocardial ischemia/reperfusion injury |
| CXCL10 | Chemokine regulated by NF-kappaB | Breast cancer microenvironment |
| CD4 | T cell marker with NF-kappaB-dependent function | Multiple sclerosis and cancer |
| REL | c-Rel subunit of NF-kappaB | Lymphoid malignancies and T cell biology [5, 8] |
How Is positive regulation of canonical NF-kappaB signal transduction Regulated?
Positive regulation of canonical NF-kappaB signaling is itself tightly regulated by post-translational modifications, including phosphorylation, ubiquitination, and deubiquitination of signaling intermediates [3, 8]. Negative feedback loops involving IkappaBalpha resynthesis and A20-mediated deubiquitination prevent sustained activation [3, 8]. In disease, genetic alterations or microenvironmental cues can override these brakes, leading to constitutive pathway activity [3, 6, 8].
positive regulation of canonical NF-kappaB signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IKBKB | Lymphoid malignancies, inflammation | Knockout and point-mutation cell lines [3, 8] |
| NFKBIA | Hodgkin lymphoma, breast cancer | Knock-in of degradation-resistant mutant [3, 6, 8] |
| IL34 | Myocardial ischemia/reperfusion injury | Overexpression in macrophage models |
| RELA | Multiple sclerosis, cancer | Knockout in CD4+ T cells |
| CXCL10 | Breast cancer microenvironment | Knockout in 4T1 cells |
Lymphoid Malignancies
Deregulated positive regulation of canonical NF-kappaB signaling is a hallmark of Hodgkin lymphoma and other lymphoid malignancies, where constitutive IKK activity and nuclear RelA/p50 drive survival and proliferation [3, 8]. Mechanisms include mutations in NFKBIA, TNFAIP3, and other pathway components that amplify positive regulation [3, 8].
Breast Cancer
Subtype-independent activation of NF-kappaB signaling has been observed in breast cancer, supporting tumor cell survival and chemokine production such as CXCL10 [6, 7]. Positive regulation in this context promotes a pro-tumorigenic microenvironment and resistance to therapy [6, 7].
Myocardial Ischemia/Reperfusion Injury
IL-34-NF-kappaB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization, highlighting the role of positive regulation in sterile inflammation.
Multiple Sclerosis and Autoimmunity
NF-kappaB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer, linking positive regulation to autoimmune neuroinflammation.
From positive regulation of canonical NF-kappaB signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is IKBKB required for canonical NF-kappaB activation? | IKBKB knockout cell line [3, 8] |
| Does a specific phosphorylation site on IkappaBalpha control signal duration? | Point-mutation knock-in of NFKBIA [3, 8] |
| Can a disease-associated NEMO mutation alter IKK activation? | Knock-in of IKBKG mutation [3, 8] |
| Does overexpression of IL-34 amplify NF-kappaB signaling? | IL34 overexpression in macrophages |
| How does RelA control T cell function in autoimmunity? | RelA knockout in CD4+ T cells |
| What is the transcriptional output of constitutive NF-kappaB in breast cancer? | Overexpression of constitutively active IKKbeta |
How to Study the positive regulation of canonical NF-kappaB signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NF-kappaB luciferase reporter | Transcriptional activity | Stimulation and perturbation studies [3, 8] |
| Phospho-immunoblot | IKK and IkappaB phosphorylation | Kinetic activation analysis [3, 8] |
| Immunofluorescence | Nuclear translocation of RelA/p50 | Spatial pathway activation [3, 8] |
| CRISPR knockout screen | Gene requirement for pathway activation | Discovery of positive regulators [5, 6] |
| RNA-seq | Target gene expression | Transcriptional output profiling [6, 7] |
| Proteomics | Protein interactions and modifications | IKK complex composition [3, 8] |
| Flow cytometry | Immune cell activation markers | T cell and macrophage studies [2, 5] |
| Spatial transcriptomics | Tissue-level pathway activity | Tumor microenvironment analysis |
Transcriptional Reporter Assays
NF-kappaB luciferase reporters measure the activity of the canonical pathway after stimulation or genetic perturbation, providing a quantitative readout of positive regulation [3, 8].
Phospho-Specific Immunoblotting
Antibodies against phospho-IKKbeta, phospho-IkappaBalpha, and phospho-p65 detect activation status and kinetics of positive regulation [3, 8].
Immunofluorescence and Imaging
Nuclear translocation of RelA/p50 can be visualized by immunofluorescence, offering spatial information on pathway activation [3, 8].
CRISPR Functional Genomics
Pooled CRISPR knockout screens identify positive regulators of canonical NF-kappaB signaling, enabling unbiased discovery of pathway components [5, 6].
How CRISPR Can Be Used to Study GO:0043123 positive regulation of canonical NF-kappaB signal transduction
Knockout
CRISPR knockout of positive regulators such as IKBKB, IKBKG, or RELA abolishes canonical NF-kappaB activation, providing causal evidence for their requirement in the pathway [3, 5, 8].
Point Mutation
Point mutations can be introduced into phosphorylation sites of IkappaBalpha or catalytic residues of IKKbeta to dissect mechanism without fully deleting the protein [3, 8].
Knock-in
Knock-in of disease-associated mutations, such as those in IKBKG, allows study of how specific alleles alter positive regulation of NF-kappaB signaling [3, 8].
Overexpression
Overexpression of ligands like IL-34 or constitutively active IKKbeta can amplify canonical NF-kappaB signaling to model disease states [2, 6].
How EDITGENE Supports positive regulation of canonical NF-kappaB signal transduction Research
Researchers studying positive regulation of canonical NF-kappaB signal transduction-related genes often need to determine whether a candidate gene is causally involved in pathway activation or disease phenotypes. EDITGENE provides CRISPR-based cell model services to enable such functional studies with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of canonical NF-kappaB signal transduction research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| Ripk1 Knockout NCTC clone 929 Cell Line | EDJ-KQ50 | Mouse | 19766 | Details Get a Quote |
| TNFRSF1A Knockout HEK293 Cell Line | EDC90705 | Human | 7132 | Details Get a Quote |
| TRAF6 Knockout HEK293 Cell Line | EDJ-KQ107 | Human | 7189 | Details Get a Quote |
| CARD11 Knockout HEK293 Cell Line | EDJ-KQ138 | Human | 84433 | Details Get a Quote |
| ERC1 Knockout HEK293 Cell Line | EDJ-KQ139 | Human | 23085 | Details Get a Quote |
| IL1B Knockout HEK293 Cell Line | EDJ-KQ140 | Human | 3553 | Details Get a Quote |
| MAP3K7 Knockout HEK293 Cell Line | EDJ-KQ142 | Human | 6885 | Details Get a Quote |
| TAB2 Knockout HEK293 Cell Line | EDJ-KQ144 | Human | 23118 | Details Get a Quote |
| FLNA Knockout HEK293 Cell Line | EDJ-KQ171 | Human | 2316 | Details Get a Quote |
| IKBKG Knockout HEK293T Cell Line | EDJ-KQ207 | Human | 8517 | Details Get a Quote |
| F2RL1 Knockout HEK293T Cell Line | EDJ-KQ222 | Human | 2150 | Details Get a Quote |
| IKBKE Knockout HEK293 Cell Line | EDJ-KQ246 | Human | 9641 | Details Get a Quote |
| CAMK2A Knockout HEK293 Cell Line | EDJ-KQ282 | Human | 815 | Details Get a Quote |
| ROR1 Knockout HEK293 Cell Line | EDJ-KQ327 | Human | 4919 | Details Get a Quote |
| PRL Knockout HEK293 Cell Line | EDJ-KQ522 | Human | 5617 | Details Get a Quote |
Displaying Records 1 To 15 Of 913 Records
- 1
- 2
- ...
- 59
- 60
- Next Page »
Frequently Asked Questions About positive regulation of canonical NF-kappaB signal transduction
What is GO:0043123?
GO:0043123 is the Gene Ontology term for positive regulation of canonical NF-kappaB signal transduction, describing any process that activates or increases the canonical NF-kappaB cascade [1, 3].
What genes are involved in positive regulation of canonical NF-kappaB signaling?
Key genes include TNF, IL1B, TRAF2, TRAF6, RIPK1, IKBKB, IKBKA, IKBKG, NFKB1, RELA, NFKBIA, and NFKBIB [3, 8].
How is canonical NF-kappaB signaling activated?
It is activated by ligand binding to receptors such as TNFR or IL-1R, leading to IKK complex activation, IkappaB phosphorylation and degradation, and nuclear translocation of RelA/p50 [3, 8].
What is the difference between canonical and non-canonical NF-kappaB signaling?
Canonical signaling depends on IKKbeta-mediated IkappaB degradation, while non-canonical signaling relies on NIK and p100 processing.
Which diseases involve deregulated positive regulation of canonical NF-kappaB signaling?
Hodgkin lymphoma, breast cancer, myocardial ischemia/reperfusion injury, and multiple sclerosis are associated with deregulated pathway activation [2, 3, 5, 6, 8].
How can CRISPR be used to study GO:0043123?
CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of specific genes in activating the canonical NF-kappaB pathway [3, 5, 6, 8].
What methods measure canonical NF-kappaB activation?
Luciferase reporters, phospho-immunoblotting, immunofluorescence, RNA-seq, and CRISPR screens are commonly used [3, 5, 6, 8].
What is the role of IKKbeta in NF-kappaB signaling?
IKKbeta is the core kinase that phosphorylates IkappaBalpha, leading to its degradation and NF-kappaB nuclear translocation [3, 8].
How does IL-34 affect NF-kappaB signaling?
IL-34 activates NF-kappaB signaling in macrophages, aggravating myocardial ischemic/reperfusion injury.
What cell models are available for NF-kappaB research?
Knockout, point-mutation, knock-in, and overexpression cell models can be generated for genes in the canonical NF-kappaB pathway [3, 5, 6, 8].
Conclusion
GO:0043123, positive regulation of canonical NF-kappaB signal transduction, is a central biological process that integrates immune and stress signals to control inflammation, survival, and proliferation [3, 8]. Its dysregulation underlies multiple human diseases, making it a prime target for mechanistic and therapeutic research [2, 3, 5, 6, 8]. CRISPR-based cell models and functional genomics provide powerful tools to dissect the positive regulators of this pathway and translate findings into clinical insights [5, 6].
References
- 1. Jenkins BH et al.. 2025. Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response.. Mol Cancer 24(1):3 PMID: 39757146
- 2. Zhuang L et al.. 2023. Interleukin-34-NF-κB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization.. EBioMedicine 95:104744 PMID: 37556943
- 3. Weniger MA et al.. 2016. NF-κB deregulation in Hodgkin lymphoma.. Semin Cancer Biol 39:32-9 PMID: 27221964
- 4. Chandrasekar AP et al.. 2024. Dynamic modulation of the non-canonical NF-κB signaling pathway for HIV shock and kill.. Front Cell Infect Microbiol 14:1354502 PMID: 38505285
- 5. Lalle G et al.. 2024. NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer.. J Exp Med 221(6) PMID: 38563819
- 6. Mitka-Krysiak E et al.. 2026. Subtype-Independent Activation of NF-κB Signaling in Breast Cancer.. Int J Mol Sci 27(9) PMID: 42123635
- 7. Jin WJ et al.. 2017. NF-κB signaling regulates cell-autonomous regulation of CXCL10 in breast cancer 4T1 cells.. Exp Mol Med 49(2):e295 PMID: 28209986
- 8. Krappmann D et al.. 2016. Mechanisms of NF-κB deregulation in lymphoid malignancies.. Semin Cancer Biol 39:3-14 PMID: 27262792
